15.05.2018 MeVis Medical Solutions AG  DE000A0LBFE4

DGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for the second quarter of fiscal year 2017/2018


 
DGAP-News: MeVis Medical Solutions AG / Key word(s): Interim Report/Half Year Results MeVis Medical Solutions AG: MeVis publishes figures for the second quarter of fiscal year 2017/2018 15.05.2018 / 15:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Decline in sales in the second quarter as expected * Revenues at EUR 4.4 million approximately 6 % below previous year's level * EBIT of EUR 3.1 million in the first half year (compared to EUR 3.6 million in the previous year) * EBIT margin stable at 38 % (previous year 37 %) * Profit after tax of EUR 2.4 million (compared to EUR 3.6 million in the previous year) Bremen, May 15, 2018 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces the results for the first half of fiscal year 2017/2018 (reporting period October 1, 2017 to March 31, 2018). Sales in the second quarter of fiscal year 2017/2018 came to EUR 3,950 k, about 6 % below previous year (EUR 4,219 k). Licensing business declined by 10 % in the second quarter to EUR 1,438 k and maintenance business fell by 5 % to EUR 1,712 k. The service business slightly decreased from EUR 825 k in the previous year period to EUR 799 k. Revenues thus amounted to EUR 8,233 k in the first half of the year (prev. year: EUR 9,756 k), of which EUR 5,710 k was attributable to the Digital Mammography segment (prev. year: EUR 5,971 k) and EUR 2,523 k to Other Diagnostics (prev. year: EUR 3,785 k). In the previous year, the revenues in the Other Diagnostics segment also included the one-off revenues of EUR 1,800 k from the sale of MeVisLab usage rights. At 69 % (prev. year: 75 %, without one-off revenue from sale of usage rights), the Digital Mammography segment continues to be the main source of revenues at the Company. Thus, the EBIT (earnings before financial result and taxes) of EUR 1,182 k was generated in the second quarter and EUR 3,136 k in the first half of the year, compared to EUR 735 k in the second quarter and EUR 3,610 k in the first half of the previous year. The EBIT margin increased slightly to 38 % compared to a previous year value of 37 %. The financial result declined significantly in the period under review to EUR -768 k (prev. year: EUR 1,095 k). In comparison to the previous year, there were significant changes in the balance of income and expenses from exchange rate differences of EUR -1,280 k (prev. year: EUR 1,180 k), as well as in the earnings of the 51 % share in MeVis BreastCare GmbH & Co. KG of EUR 444 k (prev. year: EUR -135 k), which is recognized at equity. Earnings after taxes amounted to EUR 2,366 k (prev. year: EUR 3,555 k), which corresponds to undiluted earnings per share of EUR 1.30 (prev. year: EUR 1.95). The interim report for the third quarter of fiscal year 2017/2018 will be published on August 21, 2018. --------------------------------------------------------------------------- 15.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: [email protected] Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 686065 15.05.2018


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 18,54 16,76 18,07 17,13 16,21 18,76 17,34
EBITDA1,2 9,18 7,60 8,25 5,97 4,77 7,99 3,99
EBITDA-Marge3 49,51 45,35 45,66 34,85 29,43 42,59
EBIT1,4 7,96 6,69 8,00 5,81 4,64 7,90 3,89
EBIT-Marge5 42,93 39,92 44,27 33,92 28,62 42,11 22,43
Jahresüberschuss1 5,62 7,17 8,07 5,70 4,55 7,79 4,92
Netto-Marge6 30,31 42,78 44,66 33,27 28,07 41,52 28,37
Cashflow1,7 7,32 5,52 6,55 2,89 9,13 4,86 5,85
Ergebnis je Aktie8 3,09 3,94 4,43 3,13 2,50 4,28 2,70
Dividende8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
MeVis Med. Solutions
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LBFE 25,400 Halten 46,23
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,58 10,27 1,03 7,74
KBV KCV KUV EV/EBITDA
2,59 7,90 2,67 10,79
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,95 0,95 3,74 19.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 27.05.2024 - 29.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,66% -5,34% 0,79% -23,03%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MeVis Medical Solutions AG  ISIN: DE000A0LBFE4 können Sie bei EQS abrufen


Medtech , A0LBFE , M3V , XETR:M3V